Business
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York ...
About this update from Devonian Health Group, Inc.
[{"type":"text","content":"\n\n\nDevonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\nCanada NewsWire\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\nQUEBEC, Oct. 22, 2025 /CNW/ - Devonian Health Group Inc. (\"Devonian\" or the \"Corporation\") (TSXV: GSD) (OTCQB: DVHGF), a biopharmaceutical corporation specializing in the development of prescription drugs targeting inflammatory diseases today announced that Dr. André Boulet, PhD, Chairman and Chief Executive Officer, will present at the ThinkEquity Conference on Thursday, October 30, 2025.\n\n\n\n\n\n\n\nThe event will bring together leading institutional investors, analysts, and growth-oriented companies for presentations and networking opportunities.\nEvent Details:\nConference: The ThinkEquity ConferenceLocation: Mandarin Oriental, 80 Columbus Circle, New York CityDate: October 30, 2025Presentation: 12:30 pm at the Lotus Suite WestInstitutional investors interested in meeting with Devonian Health Group's management are encouraged to contact and to register on the conference website to request a meeting.\nNon-brokered Private Placement\nThe Company also announces that it has closed a non-brokered private placement for aggregate gross proceeds of $334,500.33 (the \"Offering\"). The Offering consisted of the issuance of 1,967,649 units of the Corporation (the \"Units\") at a price of $0.17 per Unit. Each Unit consists of one common share of the Corporation (a \"Share\") and one Share purchase warrant (a \"Warrant\"). Each Warrant entitles the holder thereof to purchase one Share at an exercise price of $0.17 per Share for a period of 24 months from the date of issuance thereof.\nThe proceeds of the Offering will primarily be used to finance working capital related to the Corporation's corporate overhead and research and development activities.\nA total of $14,166.68 cash finder'...